Bicara Therapeutics Inc.
BCAX
$11.32
-$0.52-4.39%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -58.34% | -64.46% | -30.80% | -- | -- |
| Total Depreciation and Amortization | 61.90% | 103.28% | 194.74% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -30.28% | -42.46% | -54.14% | -- | -- |
| Change in Net Operating Assets | -1,066.24% | 23.29% | -46.84% | -- | -- |
| Cash from Operations | -119.17% | -89.08% | -63.83% | -- | -- |
| Capital Expenditure | 92.12% | 88.64% | 87.88% | -- | -- |
| Sale of Property, Plant, and Equipment | -100.00% | -100.00% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 91.22% | 87.31% | 98.46% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 21,443.13% | 132,179.68% | 224,736.24% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 200.00% | -- | -- | -- | -- |
| Cash from Financing | 41.74% | 31.80% | 22.58% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 23.24% | 19.15% | 14.58% | -- | -- |